Comparison of HRCT Findings Between Chronic Sarcoidosis and Chronic Hypersensitivity Pneumonitis: What to Look for Beyond Upper Lobe Fibrosis

CHEST Journal ◽  
2013 ◽  
Vol 144 (4) ◽  
pp. 590A
Author(s):  
Shahram Kahkouee ◽  
Sandbad Armand ◽  
Ramin Pourghorban ◽  
Leila Mosadegh
Keyword(s):  
Hypersensitivity Pneumonitis ◽  
Chronic Hypersensitivity Pneumonitis

Identification of Chronic Hypersensitivity Pneumonitis Biomarkers with Machine Learning and Differential Co-expression Analysis

2020 ◽  
Vol 20 ◽  
Author(s):  
Hongwei Zhang ◽  
Steven Wang ◽  
Tao Huang
Keyword(s):  
Feature Selection ◽  
Expression Analysis ◽  
Hypersensitivity Pneumonitis ◽  
Enrichment Analysis ◽  
Functional Enrichment ◽  
Great Promise ◽  
Support Vector ◽  
Svm Classifier ◽  
Clinical Tool ◽  
Chronic Hypersensitivity Pneumonitis

Aims: We would like to identify the biomarkers for chronic hypersensitivity pneumonitis (CHP) and facilitate the precise gene therapy of CHP. Background: Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease caused by hypersensitive reactions to inhaled antigens. Clinically, the tasks of differentiating between CHP and other interstitial lungs diseases, especially idiopathic pulmonary fibrosis (IPF), were challenging. Objective: In this study, we analyzed the public available gene expression profile of 82 CHP patients, 103 IPF patients, and 103 control samples to identify the CHP biomarkers. Method: The CHP biomarkers were selected with advanced feature selection methods: Monte Carlo Feature Selection (MCFS) and Incremental Feature Selection (IFS). A Support Vector Machine (SVM) classifier was built. Then, we analyzed these CHP biomarkers through functional enrichment analysis and differential co-expression analysis. Result: There were 674 identified CHP biomarkers. The co-expression network of these biomarkers in CHP included more negative regulations and the network structure of CHP was quite different from the network of IPF and control. Conclusion: The SVM classifier may serve as an important clinical tool to address the challenging task of differentiating between CHP and IPF. Many of the biomarker genes on the differential co-expression network showed great promise in revealing the underlying mechanisms of CHP.

scholarly journals Proteome Analysis of Bronchoalveolar Lavage Fluid in Chronic Hypersensitivity Pneumonitis

2012 ◽  
Vol 61 (1) ◽  
pp. 83-92 ◽  
Author(s):  
Tsukasa Okamoto ◽  
Yasunari Miyazaki ◽  
Ryutaro Shirahama ◽  
Meiyo Tamaoka ◽  
Naohiko Inase
Keyword(s):  
Bronchoalveolar Lavage ◽  
Hypersensitivity Pneumonitis ◽  
Bronchoalveolar Lavage Fluid ◽  
Proteome Analysis ◽  
Lavage Fluid ◽  
Chronic Hypersensitivity Pneumonitis

scholarly journals Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis

2017 ◽  
Vol 3 (3) ◽  
pp. 00016-2017 ◽  
Author(s):  
Ayodeji Adegunsoye ◽  
Justin M. Oldham ◽  
Evans R. Fernández Pérez ◽  
Mark Hamblin ◽  
Nina Patel ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Lung Function ◽  
Adverse Events ◽  
Immunosuppressive Therapy ◽  
Hypersensitivity Pneumonitis ◽  
Pulmonary Function Tests ◽  
Lung Function Decline ◽  
Azathioprine Therapy ◽  
Free Survival ◽  
Chronic Hypersensitivity Pneumonitis

In chronic hypersensitivity pneumonitis (CHP), lack of improvement or declining lung function may prompt use of immunosuppressive therapy. We hypothesised that use of azathioprine or mycophenolate mofetil with prednisone reduces adverse events and lung function decline, and improves transplant-free survival.Patients with CHP were identified. Demographic features, pulmonary function tests, incidence of treatment-emergent adverse events (TEAEs) and transplant-free survival were characterised, compared and analysed between patients stratified by immunosuppressive therapy. A multicentre comparison was performed across four independent tertiary medical centres.Among 131 CHP patients at the University of Chicago medical centre (Chicago, IL, USA), 93 (71%) received immunosuppressive therapy, and had worse baseline forced vital capacity (FVC) and diffusing capacity, and increased mortality compared with those who did not. Compared to patients treated with prednisone alone, TEAEs were 54% less frequent with azathioprine therapy (p=0.04) and 66% less frequent with mycophenolate mofetil (p=0.002). FVC decline and survival were similar between treatment groups. Analyses of datasets from four external tertiary medical centres confirmed these findings.CHP patients who did not receive immunosuppressive therapy had better survival than those who did. Use of mycophenolate mofetil or azathioprine was associated with a decreased incidence of TEAEs, and no difference in lung function decline or survival when compared with prednisone alone. Early transition to mycophenolate mofetil or azathioprine may be an appropriate therapeutic approach in CHP, but more studies are needed.

Role of Candida albicans in Chronic Hypersensitivity Pneumonitis

CHEST Journal ◽  
1994 ◽  
Vol 105 (1) ◽  
pp. 317-318 ◽  
Author(s):  
Masayuki Ando ◽  
Kazuko Yoshida ◽  
Himinoti Nakashima ◽  
Yuji Sugihara ◽  
Yuichi Kashida
Keyword(s):  
Candida Albicans ◽  
Hypersensitivity Pneumonitis ◽  
Chronic Hypersensitivity Pneumonitis

scholarly journals Barriers to antigen detection and avoidance in chronic hypersensitivity pneumonitis in the United States

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Kerri I. Aronson ◽  
Ronan O’Beirne ◽  
Fernando J. Martinez ◽  
Monika M. Safford
Keyword(s):  
Hypersensitivity Pneumonitis ◽  
Nominal Group Technique ◽  
The United States ◽  
Antigen Detection ◽  
Nominal Group ◽  
Clinical Knowledge ◽  
Financial Barriers ◽  
Chronic Hypersensitivity Pneumonitis ◽  
The Individual ◽  
Development And Validation

Abstract Background Chronic hypersensitivity pneumonitis (CHP) is an interstitial lung disease (ILD) caused by long term exposure to an offending antigen. Antigen avoidance is associated with improved outcomes. We are unable to identify the antigen source in approximately half of patients. When an antigen is successfully identified, patients have difficulty with avoidance. Methods We conducted three structured group discussions with US based ILD specialists utilizing the nominal group technique (NGT). Participants listed barriers to antigen detection and avoidance in CHP. Each participant ranked what they perceived to be the top three barriers in the list in terms of importance. The master list of barriers was consolidated across the three groups into themes that were prioritized based on receiving the highest rankings by participants. Results Twenty-five physicians participated; 56% had experience caring for CHP patients for ≥ 16 years. Sixty barriers to antigen detection were categorized into seven themes of which the top three were: 1. unclear significance of identified exposures; 2. gaps in clinical knowledge and testing capabilities; 3. there are many unknown and undiscovered antigens. Twenty-eight barriers to antigen avoidance were categorized into five themes of which the top three were: 1. patient limitations, financial barriers and lack of resources; 2. individual patient beliefs, emotions and attachments to the antigen source; and 3. gaps in clinical knowledge and testing capabilities. Conclusions This study uncovered challenges at the individual patient, organizational, and societal levels and ranked them in terms of level of importance. These findings provide information to guide development and validation of multidisciplinary support and interventions geared towards antigen identification and avoidance in CHP.

scholarly journals Chronic Hypersensitivity Pneumonitis Caused by Aspergillus Complicated with Pulmonary Aspergilloma

2004 ◽  
Vol 43 (10) ◽  
pp. 982-985 ◽  
Author(s):  
Akihiro YOSHIMOTO ◽  
Yukari ICHIKAWA ◽  
Yuko WASEDA ◽  
Masahide YASUI ◽  
Masaki FUJIMURA ◽  
...  
Keyword(s):  
Hypersensitivity Pneumonitis ◽  
Pulmonary Aspergilloma ◽  
Chronic Hypersensitivity Pneumonitis
Sign in / Sign up

Export Citation Format

Share Document